Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Nature, Published online: 15 May 2019; doi:10.1038/s41586-019-1215-2
Disruption of the CARMA1–BCL10–MALT1 (CBM) signalosome causes Treg cells to produce IFNγ and develop dominant anti-tumour activity in synergy with anti-PD-1 treatment, and in the absence of autoimmunity.
from Nature - Issue - nature.com science feeds https://go.nature.com/2JkPzq3
No comments